Company news

NeuroSense Therapeutics Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

NeuroSense Provides Business Update and Third Quarter 2024 Financial Results

December 17, 2024

NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC

December 10, 2024

NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS

December 3, 2024

NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price

December 1, 2024

NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND

November 20, 2024

NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission

October 27, 2024

New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients

October 23, 2024

NeuroSense Advances Plans For Early Commercialization Of Potentially Groundbreaking ALS Treatment In Canada, Targeting A $100M+ Market

October 16, 2024

NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates

October 14, 2024

NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada

October 8, 2024

NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting

October 6, 2024

NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's

September 23, 2024

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule

September 23, 2024

NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

August 29, 2024

NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price

August 6, 2024

NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial

July 31, 2024

NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression

July 8, 2024

NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug

June 30, 2024

NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results

June 23, 2024

NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal

June 20, 2024

NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit

May 19, 2024

NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning

May 13, 2024

NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients

May 6, 2024

NeuroSense Announces First Quarter 2024 Business Update

May 1, 2024

NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease

April 21, 2024

NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting

April 17, 2024

NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024

April 11, 2024

NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement

April 9, 2024

NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics

April 8, 2024

NeuroSense Announces Year End 2023 Financial Results and Provides Business Update

April 4, 2024

NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial

February 20, 2024

NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts

January 8, 2024

NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

December 26, 2023

NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial

December 13, 2023

NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints

December 4, 2023

NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023

December 3, 2023

NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business Update

November 27, 2023

NeuroSense Receives U.S. FDA Confirmation of CMC Strategy for PrimeC in Preparation for Pivotal Phase 3 in ALS and Commercial Readiness

November 12, 2023

NeuroSense Therapeutics to Present at Upcoming U.S. and European ALS Conferences

November 8, 2023

NeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023

November 5, 2023

NeuroSense Therapeutics to Participate in BIO-Europe Fall

October 31, 2023

Renowned ALS Researcher Confirms The Efficacy Of NeuroSense Therapeutics’ Lead Drug Candidate, PrimeC

October 18, 2023

NeuroSense CEO Provides Q3 2023 Update

October 16, 2023

NeuroSense's PrimeC Demonstrates Outstanding Effect on ALS Survival in Innovative iPSC Model

October 3, 2023

NeuroSense Ends its At-The-Market Equity Offering Program: Company is Fully Funded Beyond Clinical Phase 2b ALS Results

October 1, 2023

European Medicines Agency Grants NeuroSense SME Status

September 19, 2023

NeuroSense Granted Patents in Europe, Japan, and Israel for its ALS Drug PrimeC

September 18, 2023

NeuroSense to Participate in Upcoming ALS Conferences: PACTALS in Malaysia and NEALS in the U.S.

September 13, 2023

NeuroSense to Host Investor Webinar on September 12, 2023

September 5, 2023

NeuroSense Announces Second Quarter 2023 Financial Results and Provides Business Update

August 15, 2023

← Newer news releases · Older news releases →

Decks

The 5 newest of 18 decks. Every deck is listed under its year.